Karl Sitz, MD
Allergy & Immunology · Little Rock, ARNPI 1518959691
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,997 of the $19,393 with a category attached, or 61.9%. 26 manufacturers reported payments, led by CSL Behring at 52.5% of the total. Reporting peaked in 2023 at $6,968 and has fallen 75.4% since, to $1,715 in 2025. Among allergy & immunology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 304 payments — averaging $63.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$10K
- Biocryst Pharmaceuticals, Inc.$3K
- Novartis$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$559
- AstraZeneca$442
- plus $2K from 20 others
Across 333 payments — averaging $5549.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$556K
- Novartis$540K
- CSL Behring$282K
- Biocryst Pharmaceuticals, Inc.$208K
- AstraZeneca$157K
- Teva Pharmaceuticals USA, Inc.$43K
- plus $61K from 4 others
What the payments were for
- Consulting fees$190%
- Speaking & faculty fees$11,99762%
- Travel & lodging$2,04911%
- Food & beverage$5,30327%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 31 | $10,179 |
| Biocryst Pharmaceuticals, Inc. | 9 | $3,275 |
| Novartis | 31 | $1,975 |
| GSK | 91 | $1,101 |
| Regeneron Healthcare Solutions, Inc. | 25 | $559 |
| AstraZeneca | 19 | $442 |
| Sanofi | 18 | $390 |
| Grifols USA, LLC | 16 | $368 |
| Genentech USA, Inc. | 13 | $205 |
| Kaleo, Inc. | 10 | $176 |
| Octapharma USA, Inc. | 2 | $114 |
| Biocryst US Sales Co., LLC | 7 | $112 |
| Pharming Healthcare, Inc. | 5 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Pfizer | 5 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $52 |
| Shire North American Group Inc | 3 | $49 |
| ADMA Biomanufacturing LLC | 2 | $32 |
| Optinose US, Inc. | 2 | $26 |
| Alk-abello, Inc | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| Merck | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Boehringer Ingelheim | 1 | $13 |
| LEO Pharma Inc. | 1 | $13 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$103
How this compares
$19,393 in reported general payments places this provider in the 90th percentile of 26 allergy & immunology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,157 |
| Ipratropium Bromide | 18 | $800 |
| Azelastine Hcl | 29 | $730 |
| Fluticasone Propionate | 13 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $1,101 | $9,15712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 26 allergy & immunology providers in Arkansas.
Other allergy & immunology in Little Rock
- Blake ScheerLittle Rock$81K
- Jim IngramLittle Rock$62K
- Stacy GriffinLittle Rock$10K
- Ashley StonerLittle Rock$7K
- Kim JacksonLittle Rock$6K
- Adam PriceLittle Rock$4K
- Lori KagyLittle Rock$4K
- Gene FranceLittle Rock$2K
- Joshua KennedyLittle Rock$2K
- Meredith DilleyLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.